Q-omics provides the consensus-scored INSYN1 profile across patient tissues and cancer cell-line models. INSYN1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, INSYN1 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, INSYN1 RNA expression shows 19,568 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, KIRC, and GBM as cancer lineages where INSYN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INSYN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INSYN1 survival associations across molecular data types. INSYN1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INSYN1 RNA expression–survival associations across cancer types. High INSYN1 expression shows unfavorable associations in BLCA and THCA, but favorable associations in KIRP, KIRC, LGG and PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for INSYN1 RNA expression.
This table summarizes INSYN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for INSYN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INSYN1 shows lower tumor expression in KIRC, BLCA, HNSC, KIRP and COAD and higher tumor expression in KICH. The KIRC box plot shows higher INSYN1 RNA expression in normal versus tumor tissue (log2 FC = −2.110, t-test p < 0.001).
This table shows molecular features associated with INSYN1 in patient tissues and cancer cell lines. In patient samples, INSYN1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, INSYN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and OVARY.
